Medically reviewed by Archana Sharma, DO Eating well can help support your immune system and maintain strength and energy if ...

The U.S. Food and Drug Administration has approved Datroway (datopotamab deruxtecan-dlnk) for adult patients with ...

Roche’s PATHWAY HER2 (4B5) test helps identify patients with HER2-ultralow breast cancer, who may be eligible for targeted ...

The PATHWAY HER2 (4B5) test is now FDA-approved to assess HER2-ultralow status in metastatic breast cancer, expanding its ...

During a Case-Based Roundtable event, Laura Huppert, MD, discussed data and considerations around using T-DXd in breast ...

Roche has secured a new FDA approval for its first companion diagnostic test aimed at identifying breast cancer patients with ...

Traditionally, breast cancers were categorised as either HER2-positive, or HER2-negative. The introduction of the HER2-low category in 2022 expanded treatment options for some patients with ...

Patients with stage IA HER2+ breast cancer and smaller tumors had high BCSS rates whether they received adjuvant chemotherapy or not.

Among patients with advanced PIK3CA-mutated, HR-positive/HER2-negative breast cancer, Itovebi-based treatment generated ...

HR+/HER2- breast cancer is the most prevalent subtype of breast cancer, defined by cancer cells that possess hormone receptors for estrogen and/or progesterone but lack HER2 overexpression. This ...

Elacestrant (Korserdu) is available on the NHS. It is a possible treatment for oestrogen receptor-positive HER2-negative locally advanced or metastatic breast cancer with an activating ESR1 mutation ...